It’s easy to assume that more data = better models = faster identification. With AI, you can extract associations between ...

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...

Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA ...

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...

PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, ...

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the ...